Lutz Anne-Kathrin, Bauer Helen Friedericke, Ioannidis Valentin, Schön Michael, Boeckers Tobias M
Institute for Anatomy and Cell Biology, Ulm University, Ulm, Germany.
Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Ulm, Germany.
Front Synaptic Neurosci. 2022 Jun 6;14:890231. doi: 10.3389/fnsyn.2022.890231. eCollection 2022.
SHANK3 is a scaffolding protein implicated in autism spectrum disorders (ASD). Its function at excitatory glutamatergic synapses has been studied for the last two decades, however, tissue-specific expression patterns as well as its subcellular localization need to be studied in further detail. Especially the close sequence homology of SHANK3 to its protein family members SHANK2 and SHANK1 raises the emerging need for specific antibodies that are validated for the desired methodology. With this study, we aim to validate a set of commercial as well as homemade SHANK3 antibodies in Western Blotting, and synaptic immunocyto- and immunohistochemistry. We found that only a small subset of the antibodies included in this study meet the criteria of quality and specificity. Therefore, we aim to share our findings on SHANK3 antibody validation but also raise awareness of the necessity of antibody specificity testing in the field.
SHANK3是一种与自闭症谱系障碍(ASD)相关的支架蛋白。在过去二十年中,人们对其在兴奋性谷氨酸能突触中的功能进行了研究,然而,其组织特异性表达模式及其亚细胞定位仍需进一步详细研究。特别是SHANK3与其蛋白家族成员SHANK2和SHANK1的序列高度同源,这使得对适用于所需方法的特异性抗体的需求日益增加。在本研究中,我们旨在通过蛋白质免疫印迹法、突触免疫细胞化学和免疫组织化学法验证一组市售及自制的SHANK3抗体。我们发现,本研究中纳入的抗体只有一小部分符合质量和特异性标准。因此,我们旨在分享我们关于SHANK3抗体验证的研究结果,同时提高该领域对抗体特异性检测必要性的认识。